2/11 Check point inhibitors with IC in RR AML Pembrolizumab plus high dose cytarabine in RR AML. CRc 38%,mOS 11.1 mo. Responding pts had progenitor exhausted CD8+ T cells expressing TCF-1. https://t.co/H8mWgllTvs
#ICYMI: Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia by @LeukDocJZ, Ivana Gojo and colleagues. https://t.co/1YT81klcwb #lymsm https://t.co/M4LJ1VQVI2
New article: Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia https://t.co/rKQUOyGcbf #AML #leusm #hematology https://t.co/zf3TCKJCpS
RT @NickTscherniaMD: This is a subset analysis from an outstanding Phase II study of HiDAC+Pembrolizumab in r/r AML spearheaded by @LeukDoc…
This is a subset analysis from an outstanding Phase II study of HiDAC+Pembrolizumab in r/r AML spearheaded by @LeukDocJZ, who I want to thank for his exceptional mentorship. https://t.co/9NmPsu3Ia3 /3
RT @BCD_AACR: #ICYMI: Phase II Trial of Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. https://t.c…
RT @BCD_AACR: #ICYMI: Phase II Trial of Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. https://t.c…
RT @BCD_AACR: #ICYMI: Phase II Trial of Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. https://t.c…
RT @BCD_AACR: #ICYMI: Phase II Trial of Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. https://t.c…
RT @BCD_AACR: #ICYMI: Phase II Trial of Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. https://t.c…
RT @BCD_AACR: #ICYMI: Phase II Trial of Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. https://t.c…
#ICYMI: Phase II Trial of Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. https://t.co/yK6CGKOsSM. @UNC_Lineberger @hopkinskimmel @LeukDocJZ @SeroBMT1 @MDAndersonNews #AMLsm #immunotherapy https://t.co/U5OGBtNgll
RT @BCD_AACR: Just published: Phase II Trial of Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. htt…
RT @BCD_AACR: Just published: Phase II Trial of Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. htt…
RT @LeukDocJZ: I am so excited & thrilled to finally see this paper in print! Thank you to @BCD_AACR for publishing our Phase II study of H…
RT @LeukDocJZ: I am so excited & thrilled to finally see this paper in print! Thank you to @BCD_AACR for publishing our Phase II study of H…
RT @LeukDocJZ: I am so excited & thrilled to finally see this paper in print! Thank you to @BCD_AACR for publishing our Phase II study of H…
RT @BCD_AACR: Just published: Phase II Trial of Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. htt…
RT @LeukDocJZ: I am so excited & thrilled to finally see this paper in print! Thank you to @BCD_AACR for publishing our Phase II study of H…
RT @LeukDocJZ: I am so excited & thrilled to finally see this paper in print! Thank you to @BCD_AACR for publishing our Phase II study of H…
RT @BCD_AACR: Just published: Phase II Trial of Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. htt…
Just published: Phase II Trial of Pembrolizumab after High Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. https://t.co/X66NtqqTeG. @UNC_Lineberger @hopkinskimmel @LeukDocJZ @SeroBMT1 #AMLsm #immunotherapy https://t.co/e3vPHSudSI
RT @LeukDocJZ: I am so excited & thrilled to finally see this paper in print! Thank you to @BCD_AACR for publishing our Phase II study of H…
RT @LeukDocJZ: I am so excited & thrilled to finally see this paper in print! Thank you to @BCD_AACR for publishing our Phase II study of H…
I am so excited & thrilled to finally see this paper in print! Thank you to @BCD_AACR for publishing our Phase II study of HiDAC + Pembrolizumab in R/R #AML- a fantastic collaborative effort with @unc_lineberger & @hopkinskimmel. Tweetorial to foll